Takeda Pharmaceutical (NYSE:TAK) Reaches New 1-Year High – Here’s What Happened

Takeda Pharmaceutical Co. (NYSE:TAK) reached a new 52-week high on Tuesday . The stock traded as high as $18.94 and last traded at $18.6890, with a volume of 523 shares. The stock had previously closed at $18.60.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Zacks Research raised shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 2nd. Finally, Weiss Ratings raised shares of Takeda Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy”.

Takeda Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The company has a market cap of $59.87 billion, a price-to-earnings ratio of 55.01 and a beta of -0.07. The firm’s 50-day moving average price is $17.55 and its 200 day moving average price is $17.19.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, July 30th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.54. The firm had revenue of $7.50 billion for the quarter, compared to analysts’ expectations of $7.13 billion. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, sell-side analysts anticipate that Takeda Pharmaceutical Co. will post 1.54 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Julie Kim sold 89,090 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $1,523,439.00. Following the completion of the sale, the chief executive officer directly owned 391,489 shares of the company’s stock, valued at approximately $6,694,461.90. This represents a 18.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Anne Furney sold 30,868 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $527,842.80. Following the sale, the general counsel owned 204,298 shares in the company, valued at approximately $3,493,495.80. The trade was a 13.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 592,922 shares of company stock worth $10,340,896 in the last three months. 0.04% of the stock is owned by corporate insiders.

Institutional Trading of Takeda Pharmaceutical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its position in Takeda Pharmaceutical by 14.2% during the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after purchasing an additional 370,800 shares during the last quarter. Quantinno Capital Management LP increased its position in shares of Takeda Pharmaceutical by 20.6% during the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock worth $23,878,000 after purchasing an additional 219,999 shares during the last quarter. Bleakley Financial Group LLC raised its stake in shares of Takeda Pharmaceutical by 19.0% during the 1st quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock worth $7,993,000 after purchasing an additional 68,844 shares in the last quarter. Royal Bank of Canada boosted its holdings in shares of Takeda Pharmaceutical by 11.0% in the 1st quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock valued at $11,386,000 after buying an additional 60,725 shares during the last quarter. Finally, Assetmark Inc. grew its stake in shares of Takeda Pharmaceutical by 45.8% in the first quarter. Assetmark Inc. now owns 227,616 shares of the company’s stock valued at $4,215,000 after buying an additional 71,496 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Japan. The company researches, develops, manufactures and markets prescription medicines and vaccines for patients and healthcare professionals around the world.

Takeda focuses on several therapeutic areas, including gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Ninlaro for multiple myeloma and Iclusig for certain blood cancers, along with other specialty medicines and vaccines.

Founded in Osaka in 1781, Takeda has grown from a traditional pharmaceutical distributor into an international biopharmaceutical company serving markets across Japan, North America, Europe and other regions.